161 related articles for article (PubMed ID: 29169524)
1. A Case of Invasive Mucinous Pulmonary Adenocarcinoma with a CD74-NRG1 Fusion Protein Targeted with Afatinib.
Cheema PK; Doherty M; Tsao MS
J Thorac Oncol; 2017 Dec; 12(12):e200-e202. PubMed ID: 29169524
[No Abstract] [Full Text] [Related]
2. Durable Response to Afatinib in Lung Adenocarcinoma Harboring NRG1 Gene Fusions.
Gay ND; Wang Y; Beadling C; Warrick A; Neff T; Corless CL; Tolba K
J Thorac Oncol; 2017 Aug; 12(8):e107-e110. PubMed ID: 28502724
[No Abstract] [Full Text] [Related]
3. Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer.
Jones MR; Lim H; Shen Y; Pleasance E; Ch'ng C; Reisle C; Leelakumari S; Zhao C; Yip S; Ho J; Zhong E; Ng T; Ionescu D; Schaeffer DF; Mungall AJ; Mungall KL; Zhao Y; Moore RA; Ma Y; Chia S; Ho C; Renouf DJ; Gelmon K; Jones SJM; Marra MA; Laskin J
Ann Oncol; 2017 Dec; 28(12):3092-3097. PubMed ID: 28950338
[TBL] [Abstract][Full Text] [Related]
4. Afatinib successfully treated leptomeningeal metastasis during erlotinib treatment in a patient with EGFR-mutant (Exon18:G719S) lung adenocarcinoma as a second-line chemotherapy.
Tamiya M; Shiroyama T; Nishihara T; Nishida T; Hayama M; Tanaka A; Morishita N; Suzuki H; Okamoto N; Hirashima T
Asia Pac J Clin Oncol; 2017 Oct; 13(5):e531-e533. PubMed ID: 28004883
[TBL] [Abstract][Full Text] [Related]
5. A case of multiple primary lung adenocarcinoma with a CD74-NRG1 fusion protein and HER2 mutation benefit from combined target therapy.
Chen K; Li W; Xi X; Zhong J
Thorac Cancer; 2022 Nov; 13(21):3063-3067. PubMed ID: 36096509
[TBL] [Abstract][Full Text] [Related]
6. Reduction in Hepatocyte Growth Factor Serum Levels is Associated with Improved Prognosis in Advanced Lung Adenocarcinoma Patients Treated with Afatinib: a Phase II Trial.
Arrieta O; Cruz-Rico G; Soto-Perez-de-Celis E; Ramírez-Tirado LA; Caballe-Perez E; Martínez-Hernández JN; Martinez-Alvarez I; Soca-Chafre G; Macedo-Pérez EO; Astudillo-de la Vega H
Target Oncol; 2016 Oct; 11(5):619-629. PubMed ID: 27033062
[TBL] [Abstract][Full Text] [Related]
7. CD74-NRG1 fusions in lung adenocarcinoma.
Fernandez-Cuesta L; Plenker D; Osada H; Sun R; Menon R; Leenders F; Ortiz-Cuaran S; Peifer M; Bos M; Daßler J; Malchers F; Schöttle J; Vogel W; Dahmen I; Koker M; Ullrich RT; Wright GM; Russell PA; Wainer Z; Solomon B; Brambilla E; Nagy-Mignotte H; Moro-Sibilot D; Brambilla CG; Lantuejoul S; Altmüller J; Becker C; Nürnberg P; Heuckmann JM; Stoelben E; Petersen I; Clement JH; Sänger J; Muscarella LA; la Torre A; Fazio VM; Lahortiga I; Perera T; Ogata S; Parade M; Brehmer D; Vingron M; Heukamp LC; Buettner R; Zander T; Wolf J; Perner S; Ansén S; Haas SA; Yatabe Y; Thomas RK
Cancer Discov; 2014 Apr; 4(4):415-22. PubMed ID: 24469108
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series.
Cadranel J; Liu SV; Duruisseaux M; Branden E; Goto Y; Weinberg BA; Heining C; Schlenk RF; Cheema P; Jones MR; Drilon A; Trombetta D; Muscarella LA; Tolba K; Gounant V; Cseh A; Solca F; Laskin JJ; Renouf DJ
Oncologist; 2021 Jan; 26(1):7-16. PubMed ID: 32852072
[TBL] [Abstract][Full Text] [Related]
9. NRG1 fusion in a French cohort of invasive mucinous lung adenocarcinoma.
Duruisseaux M; McLeer-Florin A; Antoine M; Alavizadeh S; Poulot V; Lacave R; Rabbe N; Cadranel J; Wislez M
Cancer Med; 2016 Dec; 5(12):3579-3585. PubMed ID: 27770508
[TBL] [Abstract][Full Text] [Related]
10. Case sharing of a patient re-challenged with afatinib for EGFR-mutated advanced non-small cell lung cancer.
Lee VHF
Asia Pac J Clin Oncol; 2018 Mar; 14 Suppl 1():4-6. PubMed ID: 29508939
[TBL] [Abstract][Full Text] [Related]
11. NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents.
Laskin J; Liu SV; Tolba K; Heining C; Schlenk RF; Cheema P; Cadranel J; Jones MR; Drilon A; Cseh A; Gyorffy S; Solca F; Duruisseaux M
Ann Oncol; 2020 Dec; 31(12):1693-1703. PubMed ID: 32916265
[TBL] [Abstract][Full Text] [Related]
12. A Triple Rare E709K and L833V/H835L EGFR Mutation Responsive to an Irreversible Pan-HER Inhibitor: A Case Report of Lung Adenocarcinoma Treated with Afatinib.
Frega S; Conte P; Fassan M; Polo V; Pasello G
J Thorac Oncol; 2016 May; 11(5):e63-e64. PubMed ID: 27131295
[No Abstract] [Full Text] [Related]
13. Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas.
Costa DB; Jorge SE; Moran JP; Freed JA; Zerillo JA; Huberman MS; Kobayashi SS
J Thorac Oncol; 2016 Jun; 11(6):918-23. PubMed ID: 26964772
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lung.
Shin DH; Lee D; Hong DW; Hong SH; Hwang JA; Lee BI; You HJ; Lee GK; Kim IH; Lee YS; Han JY
Oncotarget; 2016 Oct; 7(43):69450-69465. PubMed ID: 27626312
[TBL] [Abstract][Full Text] [Related]
15. Durable response to afatinib in advanced lung adenocarcinoma harboring a novel NPTN-NRG1 fusion: a case report.
Nie X; Zhang P; Bie Z; Song C; Zhang M; Ma D; Cui D; Cheng G; Li H; Lei Y; Su X; Wu W; Li L
World J Surg Oncol; 2023 Aug; 21(1):246. PubMed ID: 37587479
[TBL] [Abstract][Full Text] [Related]
16. Promising Effects of Afatinib on Leptomeningeal Carcinomatosis Derived from Erlotinib-resistant Lung Adenocarcinoma.
Sekine A; Kato T; Iwasawa T; Baba T; Suido A; Sakuranaka H; Futaki M; Ogura T
Intern Med; 2016; 55(17):2457-61. PubMed ID: 27580550
[TBL] [Abstract][Full Text] [Related]
17. Identification of tumors with NRG1 rearrangement, including a novel putative pathogenic UNC5D-NRG1 gene fusion in prostate cancer by data-drilling a de-identified tumor database.
Ptáková N; Martínek P; Holubec L; Janovský V; Vančurová J; Grossmann P; Navarro PA; Rodriguez Moreno JF; Alaghehbandan R; Hes O; Májek O; Pešek M; Michal M; Ondič O
Genes Chromosomes Cancer; 2021 Jul; 60(7):474-481. PubMed ID: 33583086
[TBL] [Abstract][Full Text] [Related]
18. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.
Katakami N; Atagi S; Goto K; Hida T; Horai T; Inoue A; Ichinose Y; Koboyashi K; Takeda K; Kiura K; Nishio K; Seki Y; Ebisawa R; Shahidi M; Yamamoto N
J Clin Oncol; 2013 Sep; 31(27):3335-41. PubMed ID: 23816963
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic Fusion Gene CD74-NRG1 Confers Cancer Stem Cell-like Properties in Lung Cancer through a IGF2 Autocrine/Paracrine Circuit.
Murayama T; Nakaoku T; Enari M; Nishimura T; Tominaga K; Nakata A; Tojo A; Sugano S; Kohno T; Gotoh N
Cancer Res; 2016 Feb; 76(4):974-83. PubMed ID: 26837769
[TBL] [Abstract][Full Text] [Related]
20. The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations.
Yang CJ; Tsai MJ; Hung JY; Lee MH; Tsai YM; Tsai YC; Hsu JF; Liu TC; Huang MS; Chong IW
BMC Pharmacol Toxicol; 2017 Dec; 18(1):82. PubMed ID: 29237484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
